We are live on ! Find out more
CNTX icon

Context Therapeutics
CNTX

24 hedge funds and large institutions have $4.02M invested in Context Therapeutics in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

6.14% more ownership

Funds ownership: 16.15% → 22.28% (+6.1%)

4% more funds holding

Funds holding: 23 → 24 (+1)

3% more capital invested

Capital invested by funds: $3.89M → $4.02M (+$127K)

Holders
24
Holders Change
+1
Holders Change %
+4.35%
% of All Funds
0.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
7
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
OM
Opaleye Management
Massachusetts
+$1.05M
2
UBS Group
UBS Group
Switzerland
+$10.2K
3
Citadel Advisors
Citadel Advisors
Florida
+$5.85K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$2.71K
5
Renaissance Technologies
Renaissance Technologies
New York
+$2.26K

Top Sellers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
-$20K
2
TRCT
Tower Research Capital (TRC)
New York
-$2.48K

CNTX Hedge Fund Activity: Q4 2023 in Review

24 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q4 2023, worth a combined $4.02M — up 3.3% from $3.89M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new CNTX positions and 1 closed out — a net gain of 1 holder — while 7 added to existing stakes and 1 trimmed.

The largest buyer was Opaleye Management, opening a new position worth an estimated $1.05M. The largest seller was XTX Topco, exiting entirely with an estimated $20K sold.

  • 24 institutional investors held Context Therapeutics (CNTX) as of Q4 2023, up from 23 in Q3 2023.
  • Funds reported $4.02M of Context Therapeutics stock for Q4 2023, up 3.3% quarter-over-quarter.
  • 2 funds opened new Context Therapeutics positions in Q4 2023 and 1 closed out, a net change of +1 holder.
  • The largest Context Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $1.05M added.
  • The largest Context Therapeutics seller in Q4 2023 was XTX Topco, an estimated $20K sold.

Based on aggregated 13F filings for Q4 2023.